A Case Report on Delayed Diagnosis of Glioblastoma
The clinical and radiological indications of a concomitant tumour may be hidden by the rupture of a cerebral aneurysm. The goal of this study is to raise awareness about the dangers of delayed diagnosis by recounting the case of a patient who had a subarachnoid haemorrhage that hid the...
Read More
Study on Proteomic Profiling of High-grade Glioblastoma: Aspects of Biomarkers
Using two-dimensional electrophoresis (2DE), mass spectrometry (ESI LC-MS/MS), and immunodetection, researchers were able to identify and quantify different proteoforms (protein species) present in a cell line derived from a high-grade glioblastoma cell line. It was possible to obtain a 2DE protein map with a large data set of 937...
Read More
An Assessment of Mistletoe-Based Drugs Work in Synergy with Radio-Chemotherapy in the Treatment of Glioma in vitro and in vivo in Glioblastoma Bearing Mice
In Europe, extracts from the mistletoe plant Viscum album L. (VE) have long been used in complementary cancer therapy. Several compounds, such as mistletoe lectins (ML) 1-3 and viscotoxins (VT), are contained in VE, as well as a few minor ingredients. ML-1 is thought to be the primary anti-tumor...
Read More
Assessing the Impact of MGMT Promoter Methylation as a Prognostic Marker in Patients with Glioma- A Single-Center Observational Study
Background: Via promoter hypermethylation in gliomas, the MGMT gene is epigenetically silenced and this alteration has emerged as a important therapeutic response predictor. The current study was aimed at correlating O6-methylguanine-DNAmethyltransferase (MGMT promoter gene) methylation status with response to alkylating agent-based therapy in high-grade gliomas Methods: For MGMT promoter...
Read More